Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $177.63 Consensus PT from Brokerages

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have been assigned a consensus recommendation of “Buy” from the nine research firms that are presently covering the stock, MarketBeat.com reports. Nine analysts have rated the stock with a buy recommendation. The average 1-year price target among brokers that have issued a report on the stock in the last year is $177.63.

A number of brokerages have commented on KRYS. Stifel Nicolaus reaffirmed a “buy” rating and set a $204.00 price target (up previously from $178.00) on shares of Krystal Biotech in a research report on Tuesday, April 16th. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price target on shares of Krystal Biotech in a research report on Monday, May 6th.

Krystal Biotech Stock Up 0.3 %

NASDAQ KRYS opened at $208.55 on Wednesday. The company has a market capitalization of $5.96 billion, a price-to-earnings ratio of 111.52 and a beta of 0.84. Krystal Biotech has a twelve month low of $93.95 and a twelve month high of $214.98. The stock has a fifty day simple moving average of $173.92 and a 200 day simple moving average of $156.52.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, May 6th. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.17). The business had revenue of $45.25 million for the quarter, compared to analyst estimates of $47.37 million. The company’s revenue was up 452400.0% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.76) earnings per share. Research analysts expect that Krystal Biotech will post 2.06 earnings per share for the current fiscal year.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the transaction, the insider now owns 1,525,882 shares of the company’s stock, valued at approximately $268,189,020.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total value of $4,394,000.00. Following the sale, the insider now owns 1,525,882 shares in the company, valued at approximately $268,189,020.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Julian S. Gangolli sold 20,000 shares of the company’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $164.13, for a total transaction of $3,282,600.00. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

Institutional investors and hedge funds have recently made changes to their positions in the business. Jennison Associates LLC raised its holdings in shares of Krystal Biotech by 112.5% in the 4th quarter. Jennison Associates LLC now owns 724,344 shares of the company’s stock worth $89,862,000 after acquiring an additional 383,495 shares during the last quarter. Fiera Capital Corp purchased a new stake in Krystal Biotech in the 4th quarter valued at about $1,973,000. Vanguard Group Inc. increased its stake in Krystal Biotech by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 2,435,774 shares of the company’s stock valued at $302,182,000 after buying an additional 35,632 shares during the last quarter. Janney Montgomery Scott LLC purchased a new stake in Krystal Biotech in the 1st quarter valued at about $3,175,000. Finally, Braidwell LP increased its stake in Krystal Biotech by 153.2% in the 4th quarter. Braidwell LP now owns 196,200 shares of the company’s stock valued at $24,341,000 after buying an additional 118,703 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).